Ifosfamide lung cancer

Glisson B, Scott C, Komaki R, et al. Cisplatin, Ifosfamide, prolonged oral etoposide and concurrent accelerated hyperfractionated thoracic radiotherapy for patients with limited small-cell lung cancer results of RTOG 93-12 (abstract 1733). Proc Am Soc Clin Oncol 1998 17 450a. 

ICE Ifosfamide, carboplatin, etoposide Nonsmall cell lung cancer... 

Drings P, Abel U, Bulzebruck H, Stiefel P, Kleckow M, Manke HG. Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer. Cancer Chemother Pharmacol 1986 18(Suppl 2) S34-9. 

Leyvraz S, Pampallona S, Martinelli G et al (2008) A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer a randomized trial. J Natl Cancer Inst 100 533-541... 

Loehrer PJ Sr. The role of ifosfamide in small cell lung cancer. Semin Oncol 1996 23(3 Suppl 7) 40-44. 

In summary, ifosfamide, an alkylating agent with anti-neoplastic properties (1.2 g/mVday fV for 5 days), is indicated in the treatment of testicular cancer. In addition, ifosfamide has been used in lung cancer, Hodgkin s and non-Hodgkin s lymphoma, breast cancer, acute and chronic lymphocytic leukemia, ovarian cancer, and sarcomas. 

Von Rohr, A., Anderson, A., McIntosh, R., and Thatcher, N. (1991). Phase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer. Eur. J. Cancer 9,1106-1108. 

Fossella, FV., DeVore, R., Kerr, R.N., et al. (2000). Randomized phase III trial of docetaxel versus vinorelbine of ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol. 18, 2354-2362. 

Ifosfamide is active against a broad spectrum of tumors, including germ cell cancers of the testis, lymphomas, sarcomas, and carcinomas of the lung, breast, and ovary. It is thought to be more active than cyclophosphamide in germ cell cancers and sarcomas. 

Cisplatin, in combination with bleomycin, etoposide, ifosfamide, or vinblastine, cures 90% of patients with testicular cancer. Used with paclitaxel, cisplatin induces complete response in most patients with carcinoma of the ovary. Cisplatin produces responses in cancers of the bladder, head and neck, cervix, and endometrium all forms of carcinoma of the lung anal and rectal carcinomas and neoplasms of childhood. The drug sensitizes cells to radiation therapy and enhances control of locally advanced lung, esophageal, and head and neck tumors when given with irradiation. 

---